Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2006 by BioVentrix.
Recruitment status was:  Recruiting
Information provided by:
BioVentrix Identifier:
First received: May 15, 2006
Last updated: June 8, 2006
Last verified: May 2006
The purpose of the present prospective, randomized study is to investigate the clinical effectiveness of standardized left ventricular reconstruction surgery (LVR). In order to standardize the procedure, the operation will be performed with the Blue Egg, manufactured by BioVentrix, a subsidiary of CHF Technologies, Inc.

Condition Intervention Phase
Congestive Heart Failure
Ischemic Cardiomyopathy
Coronary Artery Disease
Myocardial Diseases
Device: Blue Egg Device
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart

Further study details as provided by BioVentrix:

Primary Outcome Measures:
  • A change in peak oxygen consumption (MVO2) observed in the treatment group from baseline to 6 months post surgery date is at least 1.2 ml O2/min/kg greater than the average change observed in the control group in the same time frame.

Secondary Outcome Measures:
  • Secondary objectives will examine the difference in heart failure symptoms between the two groups.

Estimated Enrollment: 100
Study Start Date: November 2005
Estimated Study Completion Date: July 2007
Detailed Description:

The primary objective of this study is to test whether a standardized Left Ventricular Reconstruction (LVR) performed with the Blue Egg device improves cardiopulmonary exercise capacity in subjects with stable New York Heart Association (NYHA) Class III or IV heart failure due to ischemic cardiomyopathy with an akinetic or dyskinetic anterior wall. This shall be accomplished by comparing changes in cardiopulmonary exercise between a group of subjects treated with LVR and optimal medical therapy (Treatment) to a group treated with optimal medical therapy alone (Control).

Secondary objectives will examine the difference in heart failure symptoms between the two groups.

The primary hypothesis is that the average change in peak oxygen consumption (MVO2) observed in the treatment group from baseline to 6 months post surgery date is at least 1.2 ml O2/min/kg greater than the average change observed in the control group in the same time frame.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Be 18 years of age or older
  • Have symptomatic heart failure consistent with NYHA Class III or IV
  • Have been treated, in the opinion of the Principal Investigator, for at least 12 weeks with an optimized pharmacological regimen, including no substantial dosage titration for the last 4 weeks. This will typically mean that the subject has had (unless intolerant) appropriate doses of angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (β-blockers) and/or aldosterone inhibitors and diuretics.
  • Have a dilated left ventricular (LV) with an LV end-systolic volume index (LVESVI) of 60 ml/m² and an akinetic or dyskinetic anterior wall
  • Have an LV ejection fraction less than or equal to 35%
  • Have an MVO2 of equal to or greater than 10, but equal to or less than 16 ml O2/min/kg
  • Have demonstrated myocardial infarction without viability on a dobutamine stress echocardiogram in a region considered for surgery. Alternatively, have demonstrated the same physiological feature with gadolinium/magnetic resonance imaging (MRI) procedures or other sophisticated methodology for viability assessment.
  • Agree to be compliant with the study protocol and willing and able to return for follow-up

Exclusion Criteria:

  • Have had a myocardial infarction within 90 days of consent
  • Be inotrope or intra-aortic balloon pump (IABP) dependent
  • Require, in the judgment of the Principal Investigator, cardiac surgery that cannot be deferred for 6 months, such as subjects with:

    • left main coronary artery disease
    • intractable ventricular arrhythmias
    • Canadian Cardiovascular Society Angina Class III or IV symptoms
    • aortic stenosis or insufficiency requiring replacement
    • 3+ or 4+ mitral regurgitation
  • Have any comorbid medical condition that is a contraindication to cardiac surgery (e.g., renal failure, coagulopathy, severe chronic obstructive pulmonary disease [COPD], cerebrovascular accident [CVA], prior stroke, known malignancy etc.)
  • Have congestive heart failure (CHF) due to a cause other than ischemic cardiomyopathy
  • Have a history of radiation therapy to the chest or mediastinum
  • Have exercise tolerance limited by a condition other than heart failure
  • Be unable to perform cardiopulmonary stress test
  • Have a history of alcohol abuse, drug addiction, or other psychosocial condition that would preclude successful participation or realization of benefit from the trial in the opinion of the Principal Investigator.
  • Be a female of child-bearing age who is pregnant or does not agree to use standard methods of birth control.
  • Carry a diagnosis of an illness other than CHF with life expectancy less than 12 months.
  • Participating in another trial (other than non-therapeutic or interventional observation) within the last 30 days or less than 60 days after completion of a heart failure drug trial.
  • Biventricular pacemaker implantation and/or activation within the past 60 days
  • Percutaneous coronary intervention (PCI) with coronary revascularization within the last 60 days.
  • More than one prior sternotomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00326690

United States, California
Cedar Sinai Department of Cardiothoracic Surgery
Los Angeles, California, United States, 90048
United States, Florida
St. Joseph's Hospital
St. Petersburg, Florida, United States, 33709
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Maryland
University of Maryland College of Medicine
Baltimore, Maryland, United States, 21201
United States, Massachusetts
University of Massachusetts
Worcester, Massachusetts, United States, 01655
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, New York
NYU College of Medicine
New York, New York, United States, 10016
United States, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania, United States, 19102
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, United States, 19104
United States, Virginia
University of Virginia College of Medicine
Charlottesville, Virginia, United States, 22908
Heart Center Leipzig
Leipzig, Germany, 39 04289
Sponsors and Collaborators
Principal Investigator: Robert R. Lazzara, MD St. Joseph's Hospital
Principal Investigator: Ulrich Jorde, MD New York College of Medicine
Principal Investigator: David Dyke, MD University of Michigan
Principal Investigator: James D. Bergin, MD University of Virginia College of Medicine
Principal Investigator: Howard J Eisen, MD Drexel University College of Medicine
Principal Investigator: Eli Gang, MD Cedar Sinai Department of Cardiothoracic Surgery
Principal Investigator: Jan F Gummert, MD Heart Center Leipzig
Principal Investigator: Mariell Jessup, MD University of Pennsylvania
Principal Investigator: Frances L Johnson, MD University of Maryland College of Medicine
Principal Investigator: Omar M. Lattouf, MD Emory University
  More Information

Publications: Identifier: NCT00326690     History of Changes
Other Study ID Numbers: BioVentrix - Blue Egg Trial™ 
Study First Received: May 15, 2006
Last Updated: June 8, 2006
Health Authority: United States: Institutional Review Board
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by BioVentrix:
Congestive Heart Failure
Coronary Artery Disease
Ischemic Cardiomyopathy
Idiopathic Cardiomyopathy

Additional relevant MeSH terms:
Heart Failure
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Arterial Occlusive Diseases
Vascular Diseases processed this record on December 09, 2016